SG Americas Securities LLC Takes $131,000 Position in UroGen Pharma Ltd. (NASDAQ:URGN)

SG Americas Securities LLC bought a new stake in shares of UroGen Pharma Ltd. (NASDAQ:URGN) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 8,707 shares of the company’s stock, valued at approximately $131,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Rice Hall James & Associates LLC increased its holdings in shares of UroGen Pharma by 6.5% in the 1st quarter. Rice Hall James & Associates LLC now owns 107,990 shares of the company’s stock worth $941,000 after buying an additional 6,631 shares during the last quarter. Swiss National Bank lifted its position in UroGen Pharma by 9.1% during the 1st quarter. Swiss National Bank now owns 47,900 shares of the company’s stock valued at $417,000 after acquiring an additional 4,000 shares during the period. JPMorgan Chase & Co. lifted its position in UroGen Pharma by 30.8% during the 1st quarter. JPMorgan Chase & Co. now owns 81,867 shares of the company’s stock valued at $714,000 after acquiring an additional 19,280 shares during the period. Bank of New York Mellon Corp lifted its position in UroGen Pharma by 11.9% during the 1st quarter. Bank of New York Mellon Corp now owns 67,486 shares of the company’s stock valued at $588,000 after acquiring an additional 7,197 shares during the period. Finally, Renaissance Technologies LLC purchased a new position in UroGen Pharma during the 1st quarter valued at about $215,000. 91.29% of the stock is owned by institutional investors.

UroGen Pharma Stock Performance

Shares of UroGen Pharma stock opened at $14.24 on Thursday. The stock has a market capitalization of $333.93 million, a PE ratio of -3.82 and a beta of 1.07. UroGen Pharma Ltd. has a 52-week low of $8.69 and a 52-week high of $24.13. The company has a 50-day simple moving average of $16.38 and a two-hundred day simple moving average of $14.59.

UroGen Pharma (NASDAQ:URGN) last issued its earnings results on Thursday, March 14th. The company reported ($0.72) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.67) by ($0.05). The business had revenue of $23.53 million for the quarter, compared to analyst estimates of $22.30 million. As a group, equities research analysts forecast that UroGen Pharma Ltd. will post -3.59 EPS for the current fiscal year.

Insider Transactions at UroGen Pharma

In other news, General Counsel Jason Drew Smith sold 4,993 shares of UroGen Pharma stock in a transaction that occurred on Wednesday, January 31st. The shares were sold at an average price of $15.74, for a total value of $78,589.82. Following the completion of the sale, the general counsel now directly owns 18,824 shares in the company, valued at $296,289.76. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, General Counsel Jason Drew Smith sold 4,993 shares of UroGen Pharma stock in a transaction that occurred on Wednesday, January 31st. The shares were sold at an average price of $15.74, for a total value of $78,589.82. Following the completion of the sale, the general counsel now directly owns 18,824 shares in the company, valued at $296,289.76. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Mark Schoenberg sold 12,000 shares of UroGen Pharma stock in a transaction that occurred on Monday, March 18th. The stock was sold at an average price of $14.05, for a total transaction of $168,600.00. Following the completion of the sale, the insider now owns 139,437 shares of the company’s stock, valued at $1,959,089.85. The disclosure for this sale can be found here. Insiders sold 20,782 shares of company stock worth $306,829 over the last three months. 11.13% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the stock. HC Wainwright reissued a “buy” rating and set a $54.00 price target on shares of UroGen Pharma in a research report on Thursday, April 4th. Oppenheimer lowered their price target on shares of UroGen Pharma from $35.00 to $34.00 and set an “outperform” rating for the company in a research report on Friday, March 15th.

About UroGen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.